Next Article in Journal
Epithelial to Mesenchymal Transition: Key Regulator of Pancreatic Ductal Adenocarcinoma Progression and Chemoresistance
Next Article in Special Issue
Tumor Immune Microenvironment in Lymphoma: Focus on Epigenetics
Previous Article in Journal
Progression in Ph-Chromosome-Negative Myeloproliferative Neoplasms: An Overview on Pathologic Issues and Molecular Determinants
Previous Article in Special Issue
Lower Survival and Increased Circulating Suppressor Cells in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma with Deficit of Vitamin D Levels Using R-GDP Plus Lenalidomide (R2-GDP): Results from the R2-GDP-GOTEL Trial
Review

PI3Kδ Inhibitors as Immunomodulatory Agents for the Treatment of Lymphoma Patients

1
Institute of Oncology Research, Faculty of Biomedical Sciences, USI, 6500 Bellinzona, Switzerland
2
IRCCS Azienda Ospedaliero-Universitaria di Bologna, 40138 Bologna, Italy
3
Istituto di Ematologia “Seràgnoli”, Dipartimento di Medicina Specialistica, Diagnostica e Sperimentale, Università degli Studi di Bologna, 40138 Bologna, Italy
4
Oncology Institute of Southern Switzerland, Ente Ospedaliero Cantonale, 6500 Bellinzona, Switzerland
*
Author to whom correspondence should be addressed.
Academic Editor: Charles H. Lawrie
Cancers 2021, 13(21), 5535; https://doi.org/10.3390/cancers13215535
Received: 20 September 2021 / Revised: 23 October 2021 / Accepted: 29 October 2021 / Published: 4 November 2021
(This article belongs to the Special Issue Tumor Immune Microenvironment in Lymphoproliferative Syndromes)
This review focuses on the effects that a class of drugs, PI3Kδ inhibitors, used for the treatment of patients with lymphoma can have not on the neoplastic cells but on the normal cells and how this effect can modulate the immune response and potentially contribute to the anti-tumor response.
The development of small molecules able to block specific or multiple isoforms of phosphoinositide 3-kinases (PI3K) has already been an active field of research for many years in the cancer field. PI3Kδ inhibitors are among the targeted agents most extensively studied for the treatment of lymphoma patients and PI3Kδ inhibitors are already approved by regulatory agencies. More recently, it became clear that the anti-tumor activity of PI3K inhibitors might not be due only to a direct effect on the cancer cells but it can also be mediated via inhibition of the kinases in non-neoplastic cells present in the tumor microenvironment. T-cells represent an important component of the tumor microenvironment and they comprise different subpopulations that can have both anti- and pro-tumor effects. In this review article, we discuss the effects that PI3Kδ inhibitors exert on the immune system with a particular focus on the T-cell compartment. View Full-Text
Keywords: lymphoma; PI3K inhibitors; T-cells; B-cells; macrophages; chemokine; cancer; tumor; immune checkpoint inhibitors lymphoma; PI3K inhibitors; T-cells; B-cells; macrophages; chemokine; cancer; tumor; immune checkpoint inhibitors
Show Figures

Figure 1

MDPI and ACS Style

Tarantelli, C.; Argnani, L.; Zinzani, P.L.; Bertoni, F. PI3Kδ Inhibitors as Immunomodulatory Agents for the Treatment of Lymphoma Patients. Cancers 2021, 13, 5535. https://doi.org/10.3390/cancers13215535

AMA Style

Tarantelli C, Argnani L, Zinzani PL, Bertoni F. PI3Kδ Inhibitors as Immunomodulatory Agents for the Treatment of Lymphoma Patients. Cancers. 2021; 13(21):5535. https://doi.org/10.3390/cancers13215535

Chicago/Turabian Style

Tarantelli, Chiara, Lisa Argnani, Pier L. Zinzani, and Francesco Bertoni. 2021. "PI3Kδ Inhibitors as Immunomodulatory Agents for the Treatment of Lymphoma Patients" Cancers 13, no. 21: 5535. https://doi.org/10.3390/cancers13215535

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop